{"id":"gonadotropin-releasing-hormone-analog","safety":{"commonSideEffects":[{"rate":"50–80","effect":"Hot flashes"},{"rate":"40–70","effect":"Decreased libido"},{"rate":"30–60","effect":"Erectile dysfunction"},{"rate":"10–20","effect":"Injection site reactions"},{"rate":"5–15","effect":"Headache"},{"rate":null,"effect":"Bone density loss (with prolonged use)"},{"rate":"5–10","effect":"Mood changes/depression"}]},"_chembl":{"chemblId":"CHEMBL263690","moleculeType":"Protein","molecularWeight":"1293.50"},"_dailymed":{"setId":"8b9226c3-ea15-4b56-8c6e-de2708f54cdd","title":"OVAPLANT-L (ALMON GONADOTROPIN-RELEASING HORMONE ANALOG) LIQUID, EXTENDED RELEASE [WESTERN CHEMICAL INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"GnRH analogs are synthetic peptides that mimic the natural GnRH hormone. Initially, they stimulate the pituitary gland, but with continuous exposure they cause desensitization and downregulation of GnRH receptors, leading to sustained suppression of gonadotropin secretion and consequent reduction in testosterone and estrogen levels. This mechanism is exploited therapeutically in hormone-dependent cancers and certain reproductive disorders.","oneSentence":"GnRH analogs bind to gonadotropin-releasing hormone receptors in the pituitary gland to suppress the release of luteinizing hormone and follicle-stimulating hormone, thereby reducing sex hormone production.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:39:08.236Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced prostate cancer"},{"name":"Breast cancer (hormone-receptor positive)"},{"name":"Endometriosis"},{"name":"Uterine fibroids"},{"name":"Precocious puberty"}]},"trialDetails":[{"nctId":"NCT05593497","phase":"PHASE2","title":"A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-05-31","conditions":"High-Risk Prostate Cancer","enrollment":30},{"nctId":"NCT04633252","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-23","conditions":"Cancer Of Prostate, Prostate Neoplasms","enrollment":86},{"nctId":"NCT03436654","phase":"PHASE2","title":"Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-06-21","conditions":"Prostate Cancer","enrollment":102},{"nctId":"NCT04325828","phase":"PHASE2","title":"A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2020-04-07","conditions":"Salivary Gland Neoplasms","enrollment":31},{"nctId":"NCT06832774","phase":"PHASE2","title":"Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-08-01","conditions":"Prostate Cancer Metastatic Disease","enrollment":192},{"nctId":"NCT05567198","phase":"","title":"Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires","status":"RECRUITING","sponsor":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","startDate":"2023-03-03","conditions":"Systemic Lupus Erythematosus (Sle), Primary Ovarian Insufficiency (Poi)","enrollment":100},{"nctId":"NCT07481942","phase":"","title":"Body Composition Assessment in Transgender Population.","status":"COMPLETED","sponsor":"Celia Bañuls","startDate":"2017-01-01","conditions":"Transgender","enrollment":70},{"nctId":"NCT06239376","phase":"NA","title":"Artificial Cycle With or Without GnRH Agonist Pre-treatment for Frozen Embryo Transfer in Adenomyosis Patients","status":"RECRUITING","sponsor":"Mỹ Đức Hospital","startDate":"2024-02-19","conditions":"Adenomyosis, IVF, Frozen Embryo Transfer","enrollment":222},{"nctId":"NCT02489318","phase":"PHASE3","title":"A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2015-11-27","conditions":"Prostate Cancer","enrollment":1052},{"nctId":"NCT03767244","phase":"PHASE3","title":"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-06-11","conditions":"Prostatic Neoplasms","enrollment":2517},{"nctId":"NCT07027124","phase":"PHASE2","title":"Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2026-03-19","conditions":"Prostate Cancer, High-risk Prostate Cancer","enrollment":40},{"nctId":"NCT02531516","phase":"PHASE3","title":"An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Aragon Pharmaceuticals, Inc.","startDate":"2015-11-19","conditions":"Prostatic Neoplasms","enrollment":1503},{"nctId":"NCT02871167","phase":"NA","title":"Risk of Infertility Related to Adjuvant Chemotherapy for Early Breast Cancer: Oocyte/Embryo Cryopreservation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2016-12","conditions":"Breast Cancer","enrollment":140},{"nctId":"NCT07476001","phase":"PHASE2","title":"Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-03","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":12},{"nctId":"NCT04037254","phase":"PHASE1, PHASE2","title":"Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring","status":"COMPLETED","sponsor":"NRG Oncology","startDate":"2019-10-08","conditions":"Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8","enrollment":22},{"nctId":"NCT07319429","phase":"PHASE2, PHASE3","title":"Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-01-25","conditions":"Endometrial Cancer, Fertility","enrollment":260},{"nctId":"NCT04557059","phase":"PHASE3","title":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Pharmaceutica N.V., Belgium","startDate":"2020-11-12","conditions":"Prostatic Neoplasms","enrollment":693},{"nctId":"NCT04293393","phase":"PHASE2","title":"Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2020-10-02","conditions":"Early Breast Cancer","enrollment":200},{"nctId":"NCT07466498","phase":"PHASE2","title":"Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Washington","startDate":"2026-08-01","conditions":"Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8","enrollment":60},{"nctId":"NCT07142551","phase":"PHASE2","title":"Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2026-03-09","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":60},{"nctId":"NCT07182279","phase":"PHASE1, PHASE2","title":"Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2025-08-01","conditions":"Prostate Cancer (Adenocarcinoma)","enrollment":29},{"nctId":"NCT01546987","phase":"PHASE3","title":"Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer","status":"COMPLETED","sponsor":"Radiation Therapy Oncology Group","startDate":"2012-05","conditions":"Prostate Cancer","enrollment":239},{"nctId":"NCT05879926","phase":"PHASE3","title":"Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-08-31","conditions":"Breast Cancer","enrollment":3960},{"nctId":"NCT07254429","phase":"PHASE2","title":"COMPASS - COpenhagen MenoPAuSe Study","status":"RECRUITING","sponsor":"Martin Blomberg Jensen","startDate":"2025-10-02","conditions":"Menopausal Osteoporosis, Bone Markers","enrollment":192},{"nctId":"NCT05700903","phase":"PHASE4","title":"Contributions to Hypertension With Androgen Deprivation Therapy","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2023-09-20","conditions":"Androgen Deprivation Therapy, Prostate Cancer, Hypertension","enrollment":10},{"nctId":"NCT05617885","phase":"PHASE1","title":"Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Praful Ravi, MB BCHir, MRCP","startDate":"2023-08-09","conditions":"Metastatic Prostate Cancer, Non-metastatic Prostate Cancer, Prostate Cancer","enrollment":9},{"nctId":"NCT06179303","phase":"PHASE2","title":"Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Washington","startDate":"2024-07-22","conditions":"Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable HER2-Negative Breast Carcinoma","enrollment":60},{"nctId":"NCT04104893","phase":"PHASE2","title":"A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2020-02-20","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":40},{"nctId":"NCT03016741","phase":"PHASE4","title":"Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Northwestern University","startDate":"2017-03-31","conditions":"Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma","enrollment":100},{"nctId":"NCT03388619","phase":"PHASE1","title":"Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-17","conditions":"Cancer Of Prostate, Prostate Neoplasms, Prostate Cancer","enrollment":30},{"nctId":"NCT04983095","phase":"NA","title":"Metastasis Directed Stereotactic Body Radiotherapy for Oligo Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Karin Soderkvist","startDate":"2021-10-27","conditions":"Prostate Cancer Metastatic, Radiation Therapy, Positron-Emission Tomography","enrollment":118},{"nctId":"NCT00066703","phase":"PHASE3","title":"Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-11-03","conditions":"Breast Cancer","enrollment":2672},{"nctId":"NCT00066690","phase":"PHASE3","title":"Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2003-12-17","conditions":"Estrogen Receptor Positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Carcinoma","enrollment":3066},{"nctId":"NCT07389187","phase":"EARLY_PHASE1","title":"Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":"mCRPC","enrollment":10},{"nctId":"NCT06523530","phase":"PHASE4","title":"Effect of a GnRH Analog on Hepatic Steatosis","status":"RECRUITING","sponsor":"Aristotle University Of Thessaloniki","startDate":"2024-11-26","conditions":"Metabolic Dysfunction-Associated Steatotic Liver Disease, Nonalcoholic Fatty Liver, Endometriosis","enrollment":62},{"nctId":"NCT06913075","phase":"NA","title":"FET in Adenomyosis","status":"NOT_YET_RECRUITING","sponsor":"Indira IVF Hospital Pvt Ltd","startDate":"2026-06-25","conditions":"Adenomyosis","enrollment":700},{"nctId":"NCT03565835","phase":"PHASE2","title":"Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2018-06-13","conditions":"Prostatic Neoplasms","enrollment":31},{"nctId":"NCT03516110","phase":"","title":"Health Related Quality of Life and Multidimensional Evaluations of Prostate Cancer Subjects Aged ≥ 60 Years Initiating Gonadotropin-Releasing Hormone (GNRH) Agonist Therapy","status":"COMPLETED","sponsor":"Ipsen","startDate":"2018-03-09","conditions":"Prostate Cancer","enrollment":831},{"nctId":"NCT06734130","phase":"PHASE2","title":"Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2025-01-10","conditions":"Metastatic Castration Sensitive Prostate Cancer","enrollment":25},{"nctId":"NCT05341128","phase":"","title":"A Study of Medical Records From Children With Central Precocious Puberty (CPP) in China","status":"COMPLETED","sponsor":"Takeda","startDate":"2023-12-13","conditions":"Central Precocious Puberty","enrollment":1477},{"nctId":"NCT04356664","phase":"PHASE2, PHASE3","title":"Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis","status":"RECRUITING","sponsor":"Hopital Foch","startDate":"2021-03-18","conditions":"Endometriosis, Adenomyosis, Infertility, Female","enrollment":180},{"nctId":"NCT06001762","phase":"PHASE2","title":"TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2023-10-05","conditions":"Breast Cancer, Early-stage Breast Cancer, High Risk Breast Carcinoma","enrollment":90},{"nctId":"NCT06059118","phase":"PHASE2","title":"Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2023-10-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT02949284","phase":"PHASE2","title":"Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2017-06-20","conditions":"Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma","enrollment":90},{"nctId":"NCT07313241","phase":"PHASE2","title":"Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-11-14","conditions":"Prostate Cancer","enrollment":68},{"nctId":"NCT05746806","phase":"NA","title":"Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-03-29","conditions":"Recurrent Prostate Cancer","enrollment":36},{"nctId":"NCT03809000","phase":"PHASE2","title":"A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"RTOG Foundation, Inc.","startDate":"2019-04-15","conditions":"Prostate Cancer","enrollment":188},{"nctId":"NCT04704115","phase":"","title":"The Therapy of Large Endometrioma","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2021-01-21","conditions":"Endometrioma, Endometriosis Ovary","enrollment":62},{"nctId":"NCT07294027","phase":"NA","title":"ICSI Versus Conventional IVF in Couples With Unexplained Infertility","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-01-01","conditions":"Unexplained Infertility","enrollment":848},{"nctId":"NCT03009981","phase":"PHASE3","title":"A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2017-03-06","conditions":"Prostate Cancer","enrollment":504},{"nctId":"NCT06195709","phase":"PHASE3","title":"ECLECTIC: EstroTEP and Circulating Biomarkers for ER-positive HER2-negative Metastatic Breast Cancer Patients","status":"RECRUITING","sponsor":"Institut Curie","startDate":"2024-05-27","conditions":"Breast Carcinoma","enrollment":300},{"nctId":"NCT07269392","phase":"PHASE4","title":"Dual Trigger With HCG and GnRH Agonist on Thawed Modified Natural Cycle Embryo Transfer","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2026-01-01","conditions":"In Vitro Fertilization (IVF), Embryo Transfer","enrollment":170},{"nctId":"NCT04025372","phase":"PHASE2","title":"INTREPId (INTermediate Risk Erection PreservatIon Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2020-06-01","conditions":"Prostate Cancer","enrollment":234},{"nctId":"NCT06106919","phase":"","title":"Ovarian Blockade During Fertility Preservation in Patients With Endometriosis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-12-18","conditions":"Endometriosis","enrollment":130},{"nctId":"NCT00001481","phase":"PHASE2","title":"The Role of Hormones in Postpartum Mood Disorders","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"1996-04-26","conditions":"Postpartum Depression","enrollment":74},{"nctId":"NCT03511196","phase":"EARLY_PHASE1","title":"Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2018-09-17","conditions":"Prostate Cancer, Stage IV Prostate Cancer, Advanced Prostate Cancer","enrollment":17},{"nctId":"NCT05189457","phase":"PHASE2","title":"First Strike, Second Strike Therapies for High Risk Metastatic Castration Sensitive Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-01-25","conditions":"Prostate Cancer, Stage IV Prostate Cancer","enrollment":32},{"nctId":"NCT06201234","phase":"PHASE2","title":"Evaluating the Addition of Elacestrant (Oral SERD) to Olaparib (PARP-inhibitor) in Patients With Advanced/Metastatic HR+/HER2- Breast Cancer","status":"RECRUITING","sponsor":"GBG Forschungs GmbH","startDate":"2024-12-13","conditions":"Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer, BRCA1 Mutation","enrollment":176},{"nctId":"NCT04565054","phase":"PHASE3","title":"Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"West German Study Group","startDate":"2020-09-02","conditions":"Breast Cancer Female","enrollment":1260},{"nctId":"NCT07164794","phase":"PHASE2","title":"Memantine Hydrochloride in Prostate Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Bin Xu","startDate":"2025-11","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)","enrollment":15},{"nctId":"NCT06369610","phase":"PHASE2","title":"Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-04-22","conditions":"Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma","enrollment":110},{"nctId":"NCT03541850","phase":"PHASE2","title":"Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2019-01-29","conditions":"PSA Level Greater Than 0.03, PSA Progression, Stage I Prostate Adenocarcinoma AJCC (American Joint Committee on Cancer ) v7","enrollment":92},{"nctId":"NCT05628363","phase":"NA","title":"Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-01-18","conditions":"Prostate Cancer, Cancer of the Prostate","enrollment":28},{"nctId":"NCT06392841","phase":"PHASE2","title":"Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations","status":"WITHDRAWN","sponsor":"Qian Qin","startDate":"2025-10","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation","enrollment":""},{"nctId":"NCT06877429","phase":"","title":"Is the Diurnal Variation in Circulating Levels of Cortisol Reflected in Follicular Fluid of Preovulatory Follicles Close to Ovulation?","status":"NOT_YET_RECRUITING","sponsor":"ART Fertility Clinics LLC","startDate":"2025-12-30","conditions":"Healthy","enrollment":20},{"nctId":"NCT05346848","phase":"PHASE2","title":"Randomized Phase II Trial on Short Term Darolutamide Concomitant to Radiation Therapy for Patients With Intermediate Unfavorable Risk Prostate Cancer","status":"RECRUITING","sponsor":"Institut Bergonié","startDate":"2023-02-24","conditions":"Prostate Cancer","enrollment":62},{"nctId":"NCT06528210","phase":"PHASE2","title":"Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate Cancer","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2025-04-16","conditions":"High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8","enrollment":""},{"nctId":"NCT04158362","phase":"PHASE3","title":"Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2020-06-11","conditions":"Cancer Metastatic","enrollment":180},{"nctId":"NCT06922318","phase":"PHASE2","title":"The COSMYC Trial (COmbined Suppression of MYC)","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2025-08-19","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":50},{"nctId":"NCT07161778","phase":"PHASE2","title":"A Trial of Triamcinolone With a GnRH Analog for Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Barts & The London NHS Trust","startDate":"2011-10-19","conditions":"Castration Resistant Prostate Cancer","enrollment":55},{"nctId":"NCT06512207","phase":"NA","title":"A Study on the Efficacy of Androgen Deprivation Therapy Combined With Anti-PD-1 Therapy in Advanced Lung Cancer","status":"RECRUITING","sponsor":"Jinzhou Medical University","startDate":"2023-12-03","conditions":"NSCLC, Stage III, NSCLC, Stage IV","enrollment":80},{"nctId":"NCT05063786","phase":"PHASE3","title":"Trastuzumab + Alpelisib +/- Fulvestrant vs Trastuzumab + CT in Patients With PIK3CA Mutated Previously Treated HER2+ Advanced BrEasT Cancer (ALPHABET)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Breast Cancer Research Group","startDate":"2021-09-14","conditions":"Advanced Breast Cancer","enrollment":27},{"nctId":"NCT01492972","phase":"PHASE3","title":"Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer","status":"RECRUITING","sponsor":"Proton Collaborative Group","startDate":"2012-01","conditions":"Prostate Cancer","enrollment":192},{"nctId":"NCT06687421","phase":"","title":"Implementation of Precision Medicine in High-risk Prostate Cancer","status":"RECRUITING","sponsor":"Andreas Josefsson","startDate":"2024-06-10","conditions":"Prostate Cancer","enrollment":5500},{"nctId":"NCT05649943","phase":"NA","title":"Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment","status":"RECRUITING","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2023-03-01","conditions":"Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":566},{"nctId":"NCT03275181","phase":"","title":"Effect of Androgen Deprivation Therapy on Cardiovascular Function in Prostate Cancer","status":"COMPLETED","sponsor":"Kansas State University","startDate":"2017-08-01","conditions":"Prostate Cancer","enrollment":18},{"nctId":"NCT06150703","phase":"PHASE3","title":"Luteal Phase Support With GnRH Agonist After GnRH Agonist Triggering in IVF/ICSI Cycles","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-06-27","conditions":"In Vitro Fertilization, ICSI Intracytoplasmic Spermatozoid Injection","enrollment":652},{"nctId":"NCT06455969","phase":"PHASE4","title":"Adaptions and Resiliency to Multi-Stressor OpeRations","status":"RECRUITING","sponsor":"Bradley Nindl","startDate":"2024-07-15","conditions":"Musculoskeletal Injury, Hypogonadism","enrollment":120},{"nctId":"NCT07128394","phase":"NA","title":"Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment","status":"RECRUITING","sponsor":"Nanjing University","startDate":"2024-02-01","conditions":"Infertility, Female, Luteinizing Hormone (LH)","enrollment":590},{"nctId":"NCT07127315","phase":"","title":"Assessing Gonadotropin-Releasing Hormone Agonists Benefit in Preserving the Ovarian Function in Premenopausal Breast Cancer Patients During Chemotherapy","status":"COMPLETED","sponsor":"Helwan University","startDate":"2022-07-01","conditions":"Gonadotropin Releasing Hormone Agonists, Ovarian Function, Premenopausal","enrollment":100},{"nctId":"NCT03630666","phase":"NA","title":"Comparison of Intermittent Androgen Deprivation Therapy With or Without Irradiation Recovery in Prostate Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2018-12-04","conditions":"Prostate Cancer, Oligometastasis","enrollment":256},{"nctId":"NCT05473039","phase":"NA","title":"Effect of a Multivitamin Supplement With Probiotic (Seidivid Ferty4®) on Oocyte Retrieval and Quality","status":"COMPLETED","sponsor":"SEID S.A.","startDate":"2022-07-11","conditions":"Reproductive Techniques, Assisted","enrollment":196},{"nctId":"NCT05316935","phase":"PHASE2, PHASE3","title":"GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients","status":"RECRUITING","sponsor":"Xiaojun Chen","startDate":"2022-07-13","conditions":"Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance","enrollment":80},{"nctId":"NCT06390904","phase":"PHASE2, PHASE3","title":"GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Xiaojun Chen","startDate":"2022-07-13","conditions":"Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity","enrollment":29},{"nctId":"NCT06379113","phase":"PHASE2, PHASE3","title":"GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients","status":"RECRUITING","sponsor":"Xiaojun Chen","startDate":"2022-07-13","conditions":"Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance","enrollment":29},{"nctId":"NCT05765500","phase":"PHASE2","title":"RecoverPC: Relugolix vs GnRH Agonist in Quality of Life","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-02-12","conditions":"Prostate Cancer, Prostatic Neoplasms","enrollment":110},{"nctId":"NCT06280677","phase":"","title":"Aurora Test for ART Donor Patients (AURORA-Donor)","status":"RECRUITING","sponsor":"Fertiga, Belgium","startDate":"2024-02-16","conditions":"Infertility","enrollment":160},{"nctId":"NCT04203381","phase":"NA","title":"Skeletal Health and Bone Marrow Composition Among Youth","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amy DiVasta, MD","startDate":"2020-09-15","conditions":"Gender Dysphoria in Children, Puberty, Bone Development","enrollment":80},{"nctId":"NCT02357654","phase":"PHASE4","title":"GnRH for Luteal Support in IVF/ICSI/FET Cycles","status":"RECRUITING","sponsor":"University Reproductive Associates","startDate":"2015-11","conditions":"Infertility","enrollment":350},{"nctId":"NCT03298087","phase":"PHASE2","title":"Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer","status":"COMPLETED","sponsor":"VA Office of Research and Development","startDate":"2018-07-01","conditions":"Newly Diagnosed Oligometastatic Prostate Cancer","enrollment":28},{"nctId":"NCT06995261","phase":"","title":"Follitropin Delta in Long GnRH-agonist Protocol","status":"RECRUITING","sponsor":"Prof. Dr. med. M.Sc. Georg Griesinger","startDate":"2025-07-09","conditions":"Infertility (IVF Patients), Infertility, Infertility Drugs","enrollment":350},{"nctId":"NCT05458856","phase":"PHASE3","title":"Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate","status":"COMPLETED","sponsor":"Ipsen","startDate":"2022-08-30","conditions":"Prostate Cancer","enrollment":147},{"nctId":"NCT07065539","phase":"NA","title":"GnRH Agonist Pretreatment Duration and Letrozole Supplementation in Frozen Embryo Transfer for Adenomyosis Patients","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital, Sun Yat-Sen University","startDate":"2025-07-20","conditions":"Adenomyosis of Uterus, Frozen Embryo Transfer (FET)","enrollment":432},{"nctId":"NCT00963417","phase":"NA","title":"Study of Bone Mineral Density in Women With Breast Cancer Treated With Triptorelin and Tamoxifen or Exemestane on Protocol IBCSG 25-02","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2009-08-03","conditions":"Breast Cancer, Osteoporosis","enrollment":119},{"nctId":"NCT04760691","phase":"PHASE1","title":"Pre-Exposure Prophylaxis (PrEP)- Gender Affirming Hormone Therapy (GAHT) Interactions in TGW","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2021-03-01","conditions":"Hiv, Prophylaxis, Transgender","enrollment":13},{"nctId":"NCT00001521","phase":"PHASE3","title":"Three Drug Combination Therapy Versus Conventional Treatment of Children With Congenital Adrenal Hyperplasia","status":"COMPLETED","sponsor":"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","startDate":"1995-06-08","conditions":"Congenital Adrenal Hyperplasia (CAH)","enrollment":66},{"nctId":"NCT04482374","phase":"","title":"Puberty Suppression and Cardiometabolic Health","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2020-08-10","conditions":"Transgenderism, Insulin Sensitivity/Resistance, Endothelial Dysfunction","enrollment":30},{"nctId":"NCT00667069","phase":"PHASE3","title":"Triptorelin and Radiation Therapy in Treating Patients Who Have Undergone Surgery for Intermediate-Risk Stage III or Stage IV Prostate Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2008-04-07","conditions":"Prostate Cancer","enrollment":424},{"nctId":"NCT06985186","phase":"PHASE4","title":"Does The Addition Of Letrozole To Ultra-Long GnRH Agonists Help Adenomyosis Patients in ART? The AURA Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Palermo","startDate":"2025-06","conditions":"Adenomyosis of Uterus, Infertility Assisted Reproductive Technology","enrollment":162},{"nctId":"NCT05694819","phase":"PHASE2","title":"Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Center Hospital East","startDate":"2020-04-17","conditions":"Salivary Gland Cancer","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":442,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["GnRH Agonist","GnRH Analog","Gonadotropin-Releasing Hormone Agonist","Gonadotropin-Releasing Hormone Analogue","LH-RH agonist"],"phase":"marketed","status":"active","brandName":"Gonadotropin-releasing Hormone Analog","genericName":"Gonadotropin-releasing Hormone Analog","companyName":"Rutgers, The State University of New Jersey","companyId":"rutgers-the-state-university-of-new-jersey","modality":"Biologic","firstApprovalDate":"","aiSummary":"GnRH analogs bind to gonadotropin-releasing hormone receptors in the pituitary gland to suppress the release of luteinizing hormone and follicle-stimulating hormone, thereby reducing sex hormone production. Used for Advanced prostate cancer, Breast cancer (hormone-receptor positive), Endometriosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}